SciBrunch completes USD 35M+ Pre‑A series financing, with recent two rounds totaling USD 65M

SciBrunch has announced the successful closing of an oversubscribed Pre-A Series financing round, raising more than USD 35 million. This round was led by the well-known biopharmaceutical investment firm Highlight Capital (HLC), with participation from InnoPinnacle Fund. Existing shareholders, including Hankang Capital, BioTrack Capital, LongRiver Investments, and Elikon Venture, continued their support with additional investment. This financing round follows SciBrunch's angel funding secured in June 2025, marking the second round of funding completed by SciBrunch within a year. The combined total raised across these two rounds amounts to USD 65 million.

The proceeds from this financing round will be primarily allocated to:

Accelerating the clinical development of the core pipeline asset SPR1020. As a next-generation, highly selective PARP1 inhibitor with demonstrated brain-penetrant properties, SPR1020 achieved its first patient dosing on January 8, 2026.

Advancing the Investigational New Drug (IND)-enabling development of a novel molecular glue-type RAS inhibitor. This program aims to explore the clinical potential in RAS mutation-driven refractory tumors (such as colorectal cancer, pancreatic cancer, and non-small cell lung cancer), with the goal of establishing a leading therapeutic option for RAS-driven cancers across multiple dimensions.